199 related articles for article (PubMed ID: 19157801)
41. Overexpression of the multidrug efflux pumps MexCD-OprJ and MexEF-OprN is associated with a reduction of type III secretion in Pseudomonas aeruginosa.
Linares JF; López JA; Camafeita E; Albar JP; Rojo F; Martínez JL
J Bacteriol; 2005 Feb; 187(4):1384-91. PubMed ID: 15687203
[TBL] [Abstract][Full Text] [Related]
42. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 6: exploration of aromatic substituents.
Yoshida K; Nakayama K; Yokomizo Y; Ohtsuka M; Takemura M; Hoshino K; Kanda H; Namba K; Nitanai H; Zhang JZ; Lee VJ; Watkins WJ
Bioorg Med Chem; 2006 Dec; 14(24):8506-18. PubMed ID: 16979895
[TBL] [Abstract][Full Text] [Related]
43. Effect of single-dose carbapenem exposure on transcriptional expression of bla
Choudhury D; Paul D; Ghosh AS; Das Talukdar A; Dutta Choudhury M; Maurya AP; Dhar Chanda D; Chakravarty A; Bhattacharjee A
J Glob Antimicrob Resist; 2016 Dec; 7():72-77. PubMed ID: 27668722
[TBL] [Abstract][Full Text] [Related]
44. Inner membrane efflux components are responsible for beta-lactam specificity of multidrug efflux pumps in Pseudomonas aeruginosa.
Srikumar R; Li XZ; Poole K
J Bacteriol; 1997 Dec; 179(24):7875-81. PubMed ID: 9401051
[TBL] [Abstract][Full Text] [Related]
45. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 5: Carbon-substituted analogues at the C-2 position.
Yoshida K; Nakayama K; Kuru N; Kobayashi S; Ohtsuka M; Takemura M; Hoshino K; Kanda H; Zhang JZ; Lee VJ; Watkins WJ
Bioorg Med Chem; 2006 Mar; 14(6):1993-2004. PubMed ID: 16290941
[TBL] [Abstract][Full Text] [Related]
46. Mutations in PA3574 (nalD) lead to increased MexAB-OprM expression and multidrug resistance in laboratory and clinical isolates of Pseudomonas aeruginosa.
Sobel ML; Hocquet D; Cao L; Plesiat P; Poole K
Antimicrob Agents Chemother; 2005 May; 49(5):1782-6. PubMed ID: 15855496
[TBL] [Abstract][Full Text] [Related]
47. In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneumonia.
Croisier D; Martha B; Piroth L; Chavanet P
Int J Antimicrob Agents; 2008 Dec; 32(6):494-8. PubMed ID: 18804348
[TBL] [Abstract][Full Text] [Related]
48. A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa.
Mesaros N; Glupczynski Y; Avrain L; Caceres NE; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2007 Mar; 59(3):378-86. PubMed ID: 17289770
[TBL] [Abstract][Full Text] [Related]
49. A Novel indole compound that inhibits Pseudomonas aeruginosa growth by targeting MreB is a substrate for MexAB-OprM.
Robertson GT; Doyle TB; Du Q; Duncan L; Mdluli KE; Lynch AS
J Bacteriol; 2007 Oct; 189(19):6870-81. PubMed ID: 17644596
[TBL] [Abstract][Full Text] [Related]
50.
Abdelmalek S; Hajar M; Salah L; Abdel-Halim H
Microb Drug Resist; 2024 Feb; 30(2):73-81. PubMed ID: 38150012
[TBL] [Abstract][Full Text] [Related]
51. In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy.
Le Thomas I; Couetdic G; Clermont O; Brahimi N; Plésiat P; Bingen E
J Antimicrob Chemother; 2001 Oct; 48(4):553-5. PubMed ID: 11581237
[TBL] [Abstract][Full Text] [Related]
52. Beta-lactamase inhibitors are substrates for the multidrug efflux pumps of Pseudomonas aeruginosa.
Li XZ; Zhang L; Srikumar R; Poole K
Antimicrob Agents Chemother; 1998 Feb; 42(2):399-403. PubMed ID: 9527793
[TBL] [Abstract][Full Text] [Related]
53. Effect of sulbactam on anti-pseudomonal activity of beta-lactam antibiotics in cells producing various levels of the MexAB-OprM efflux pump and beta-lactamase.
Nakae T; Saito K; Nakajima A
Microbiol Immunol; 2000; 44(12):997-1001. PubMed ID: 11220688
[TBL] [Abstract][Full Text] [Related]
54. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa.
Masuda N; Sakagawa E; Ohya S; Gotoh N; Tsujimoto H; Nishino T
Antimicrob Agents Chemother; 2000 Dec; 44(12):3322-7. PubMed ID: 11083635
[TBL] [Abstract][Full Text] [Related]
55. Role of the membrane fusion protein in the assembly of resistance-nodulation-cell division multidrug efflux pump in Pseudomonas aeruginosa.
Mokhonov VV; Mokhonova EI; Akama H; Nakae T
Biochem Biophys Res Commun; 2004 Sep; 322(2):483-9. PubMed ID: 15325256
[TBL] [Abstract][Full Text] [Related]
56. In vitro and in vivo potency of polymyxin B against IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa.
Miyajima Y; Hiramatsu K; Mizukami E; Morinaga R; Ishii H; Shirai R; Kishi K; Tokimatsu I; Saikawa T; Kadota J
Int J Antimicrob Agents; 2008 Nov; 32(5):437-40. PubMed ID: 18715759
[TBL] [Abstract][Full Text] [Related]
57. Contribution of the MexX-MexY-oprM efflux system to intrinsic resistance in Pseudomonas aeruginosa.
Masuda N; Sakagawa E; Ohya S; Gotoh N; Tsujimoto H; Nishino T
Antimicrob Agents Chemother; 2000 Sep; 44(9):2242-6. PubMed ID: 10952562
[TBL] [Abstract][Full Text] [Related]
58. MexXY RND pump of
Singh M; Sykes EME; Li Y; Kumar A
Microbiology (Reading); 2020 Nov; 166(11):1095-1106. PubMed ID: 32909933
[TBL] [Abstract][Full Text] [Related]
59. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model.
Alou L; Aguilar L; Sevillano D; Giménez MJ; Echeverría O; Gómez-Lus ML; Prieto J
J Antimicrob Chemother; 2005 Feb; 55(2):209-13. PubMed ID: 15650000
[TBL] [Abstract][Full Text] [Related]
60. In vivo efficacy of ceftolozane against Pseudomonas aeruginosa in a rabbit experimental model of pneumonia: comparison with ceftazidime, piperacillin/tazobactam and imipenem.
Bretonnière C; Boutoille D; Caillon J; Desessard C; Guitton C; Potel G; Jacqueline C
Int J Antimicrob Agents; 2014 Sep; 44(3):218-21. PubMed ID: 25108877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
